<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452789</url>
  </required_header>
  <id_info>
    <org_study_id>11F.193</org_study_id>
    <secondary_id>R01DA029076-01A1</secondary_id>
    <nct_id>NCT01452789</nct_id>
  </id_info>
  <brief_title>Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome</brief_title>
  <official_title>A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after
      utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was
      associated with a ~30% reduction length of treatment compared to standard of care morphine.
      Due to the subjective nature of the scoring instrument, efficacy in a blinded trial is needed
      to unequivocally establish the superiority of buprenorphine over morphine. The primary
      objective of the trial is to compare length of treatment using sublingual buprenorphine or
      oral morphine solution in the pharmacologic treatment of the NAS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single-site, randomized, double-blind, double-dummy, parallel-group clinical
      trial. Potential patients were identified in the pre-natal period by staff of the Thomas
      Jefferson University Family center. Mothers who provided consent were contacted upon
      admission to TJUH. Inclusion and exclusion criteria were reassessed during the peri-partum
      period and study details reviewed again with the mother, and where possible, the father of
      the child. Women admitted to TJUH with in utero exposure to opioids who are not in the Family
      Center present were screened and approached for consent during their inpatient stay.

      Infants at risk for NAS had abstinence assessed using the MOTHER scoring instrument, which is
      based upon Finnegan Score and will hereafter be called the &quot;NAS score&quot;. This is the standard
      instrument used at TJUH. A need for initiation of treatment was defined as any consecutive 3
      scores adding up to ≥ 24 or any single score ≥12, and the clinical decision of the attending
      physician that the infant requires pharmacologic therapy. Randomization took place following
      reaching of the threshold for initiation of treatment and a re-review of inclusion and
      exclusion criteria. Patients were randomized to treatment groups of 1) oral
      morphine/sublingual placebo for buprenorphine or 2) oral placebo for morphine/sublingual
      buprenorphine. Randomization was stratified according to in utero exposure to methadone or
      buprenorphine. Oral morphine or placebo for morphine was administered by mouth every 4 hours,
      while buprenorphine or placebo for buprenorphine was administered every 8 hours. NAS scores
      were obtained every 4 hours. Dose assessment took place on a daily basis. If the three
      previous NAS scores are greater than 24, a dose advancement took place (at the discretion of
      the neonatologist). Morphine/placebo will be increased by 20% and buprenorphine/placebo will
      be increased by 25%. NNNS scoring took place for all infants who provide consent at day 2-3
      of life, or earlier if pharmacologic treatment is required before this time, on day 10 of
      life, and in the post therapy period (but no later than corrected post gestational age of 46
      weeks).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Treatment</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.</time_frame>
    <description>This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>Duration of hospital stay is an expected average of 5 weeks.</time_frame>
    <description>This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Supplemental Phenobarbital Treatment.</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.</time_frame>
    <description>This endpoint will compare requirement number of patients who require use of supplemental phenobarbital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.</time_frame>
    <description>Adverse events will be collected, graded by severity, and assessed for causality referent to study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Neonatal Abstinence Syndrome</condition>
  <arm_group>
    <arm_group_label>sublingual buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the group that received active sublingual buprenorphine and placebo for oral morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the group that received active oral morphine and placebo for sublingual buprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sublingual buprenorphine</intervention_name>
    <description>Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
    <arm_group_label>sublingual buprenorphine</arm_group_label>
    <other_name>Buprenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral morphine</intervention_name>
    <description>Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
    <arm_group_label>oral morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 37 weeks gestation

          -  Exposure to opiates in utero

          -  Demonstration of signs and symptoms of neonatal abstinence syndrome requiring
             treatment

        Exclusion Criteria:

          -  Major congenital malformations and/or intrauterine growth retardation

          -  Medical illness requiring intensification of medical therapy. This includes, but is
             not limited to suspected sepsis requiring antibiotic therapy.

          -  Hypoglycemia requiring treatment with intravenous dextrose.

          -  Bilirubin &gt;20 mg/dL (The need for phototherapy is not exclusionary)

          -  Concomitant benzodiazepine or severe alcohol abuse , self-report of regular use of
             alcohol or of benzodiazepines use in the past 30 days, and/or receipt of
             benzodiazepines by prescription (as determined by self-report or intake urine) by the
             mother 30 days prior to birth,

          -  Concomitant use of Cytrochrom (CYP) 3A inhibitors (erythromycin, clarithromycin,
             ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin,
             carbamazepine, phenobarbital) prior to initiation of NAS treatment

          -  Seizure activity or other neurologic abnormality

          -  Breast feeding

          -  Inability of mother to give informed consent due to co-morbid psychiatric diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter K Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jeffeson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hosptial</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011 Mar;106(3):574-80. doi: 10.1111/j.1360-0443.2010.03170.x. Epub 2010 Oct 6.</citation>
    <PMID>20925688</PMID>
  </reference>
  <reference>
    <citation>Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep;122(3):e601-7. doi: 10.1542/peds.2008-0571. Epub 2008 Aug 11.</citation>
    <PMID>18694901</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <results_first_submitted>September 20, 2019</results_first_submitted>
  <results_first_submitted_qc>March 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2020</results_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neonatal abstinence syndrome</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>morphine</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Abstinence Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Interested investigators should contact the PI listed on clinicaltrials.gov. Study protocol, statistical action plan and informed consent are available in the public domain as a supplement to the publication https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662132/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Available after Jan. 1, 2020</ipd_time_frame>
    <ipd_access_criteria>PI and co-investigators will have discretion to share data with potential collaborators.</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From November 1, 2011, to May 29, 2016, we enrolled term infants (≥37 weeks of gestation) who had been exposed to opioids in utero and had signs and symptoms of the neonatal abstinence syndrome.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sublingual Buprenorphine</title>
          <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
        </group>
        <group group_id="P2">
          <title>Oral Morphine</title>
          <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sublingual Buprenorphine</title>
          <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
        </group>
        <group group_id="B2">
          <title>Oral Morphine</title>
          <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>gestational age months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" lower_limit="37" upper_limit="42"/>
                    <measurement group_id="B2" value="39" lower_limit="37" upper_limit="41"/>
                    <measurement group_id="B3" value="38.7" lower_limit="37" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Treatment</title>
        <description>This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution.</description>
        <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Buprenorphine</title>
            <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
          </group>
          <group group_id="O2">
            <title>Oral Morphine</title>
            <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Treatment</title>
          <description>This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution.</description>
          <population>Intention to treat</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="3" upper_limit="67"/>
                    <measurement group_id="O2" value="28" lower_limit="13" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>van Elteren</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalization</title>
        <description>This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution.</description>
        <time_frame>Duration of hospital stay is an expected average of 5 weeks.</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Buprenorphine</title>
            <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
          </group>
          <group group_id="O2">
            <title>Oral Morphine</title>
            <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospitalization</title>
          <description>This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution.</description>
          <population>Intention to treat</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="7" upper_limit="71"/>
                    <measurement group_id="O2" value="33" lower_limit="18" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>van Elteren</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Supplemental Phenobarbital Treatment.</title>
        <description>This endpoint will compare requirement number of patients who require use of supplemental phenobarbital.</description>
        <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Buprenorphine</title>
            <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
          </group>
          <group group_id="O2">
            <title>Oral Morphine</title>
            <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Supplemental Phenobarbital Treatment.</title>
          <description>This endpoint will compare requirement number of patients who require use of supplemental phenobarbital.</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Adverse events will be collected, graded by severity, and assessed for causality referent to study drug.</description>
        <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Buprenorphine</title>
            <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
          </group>
          <group group_id="O2">
            <title>Oral Morphine</title>
            <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Adverse events will be collected, graded by severity, and assessed for causality referent to study drug.</description>
          <population>Intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from allocation through discharge from hospital, up to a maximum of 71 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sublingual Buprenorphine</title>
          <description>sublingual buprenorphine: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose</description>
        </group>
        <group group_id="E2">
          <title>Oral Morphine</title>
          <description>oral morphine: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>supraglottoplasty</sub_title>
                <description>Associated with Pierre Robin syndrome</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>abdominal distension, oral thrush, allergic colitis, laryngomalacia, gastrointestinal reflux, gastrostomy tube placement</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>diaper rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Eczematous, acneiform or vesicular; paronychia</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Umbilical granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter Kraft</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215 955 9077</phone>
      <email>walter.kraft@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

